Sinovac Biotech has concluded the initial stages of a Phase I trial of its proprietary inactivated pandemic influenza vaccine (human-used avian flu vaccine), Panflu.

The purpose of Phase I was to provide an evaluation of vaccine's safety and immunogenicity and a reference for determining the vaccine dosage for a Phase II trial. The trial was conducted at the Beijing Sino-Japan Friendship Hospital in Beijing, using a double-blind, randomized method of testing.